OSR Holdings Enhances Leadership with Dr. Andreas Niethammer as CMO for Vaximm AG
OSR Holdings Appoints Dr. Andreas Niethammer as CMO of Vaximm AG
OSR Holdings, Inc., a healthcare company traded on NASDAQ under the symbol OSRH, has made a significant addition to its executive team by appointing Dr. Andreas Niethammer as the Chief Medical Officer of Vaximm AG, a subsidiary focused on innovative cancer therapies. This announcement was made on July 15, 2025, and reflects OSR Holdings’ commitment to enhancing healthcare outcomes globally.
A Leader in Oncology
Dr. Niethammer is a distinguished figure in the field of oncology, boasting over 20 years of expertise in cancer immunotherapy and clinical development. His career is marked by previous leadership roles at renowned biopharmaceutical firms such as Fate Therapeutics, Pfizer, and Aardvark Therapeutics. His profound experience is not only in developing clinical strategies but also in advancing groundbreaking immuno-oncology platforms, including VXM01, a novel T-cell activator now in clinical trials.
Background and Contributions
Dr. Niethammer co-founded Vaximm, having initially published pivotal research on oral T-cell vaccination while affiliated with the Scripps Research Institute. His contributions in this arena have been crucial in catalyzing the development of oral therapies aimed at stimulating the immune response against cancer. Under his guidance, Vaximm progressed its lead candidate, VXM01, through first-in-human clinical trials targeting aggressive cancers like pancreatic cancer and glioblastoma.
Statements From Leadership
Dr. Constance Höfer, Chief Science Officer at OSR Holdings, expressed enthusiasm about Dr. Niethammer's return to Vaximm, emphasizing his rich understanding of the company’s foundational scientific principles and extensive global clinical development experience. "His unique skill set equips him to lead the clinical advancement of VXM01 while also expanding our oncology pipeline as well as exploring other disease areas," she stated.
Dr. Niethammer himself expressed excitement about rejoining Vaximm, underlining the collaborative potential with OSR Holdings’ resources. He mentioned that they are poised to accelerate the creation of oral immunotherapies, which could potentially revolutionize treatment options for difficult cancers and other diseases with significant unmet medical needs.
Educational Credentials
Dr. Niethammer achieved his M.D. and Ph.D. from the University of Heidelberg and is currently an associate professor of oncology at Heidelberg University. His authoritative presence in the field is reinforced by numerous publications in peer-reviewed journals, establishing him as a leader in researching T-cell-based vaccines for cancer.
About Vaximm AG
Vaximm is recognized as a Swiss-German biotech entity dedicated to developing oral T-cell immunotherapies for cancer patients. Its proprietary platform is designed to activate targeted T-cells through oral administration, and its lead program, VXM01, has completed early-phase clinical trials, showcasing promise in treating pancreatic cancer and glioblastoma.
OSR Holdings Inc.
OSR Holdings, Inc. (NASDAQ: OSRH) operates as a global healthcare holding company focused on biomedical innovations that aim to improve health and wellness, thereby enhancing global health outcomes. Through its subsidiaries, OSR Holdings is actively involved in several areas, including immuno-oncology and regenerative medicine, with a vision to enhance patient care through pioneering research and development initiatives. The company’s strategic direction is aimed at acquiring and nurturing a portfolio of innovative healthcare firms, ensuring that they contribute positively to patient outcomes through next-generation therapies.
As Vaximm embarks on this exciting new phase under Dr. Niethammer’s leadership, the potential for breakthroughs in the treatment of cancer remains a top priority, reinforcing OSR Holdings' dedication to advancing healthcare solutions worldwide.